Ardelyx (ARDX)Chief Patient Officer sold ~$306K
Laura A Williams, Chief Patient Officer at Ardelyx, sold ~$306K of Ardelyx shares.
- ~$306K
- Approx. value · 50K sh @ $6.12
- 396K
- Holds after · shares reported
- Traded
- Aug 26, 2025
- Filed
- Aug 28, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Aug 21, 2025Insider · 6 peopleInsiders: 6 sales (~$507K)
- Aug 26, 2025 · this disclosureInsiderOfficer sold ~$306K of ARDX shares in the open market
What came next
- Aug 26, 2025InsiderOfficer sold ~$184K of ARDX shares in the open market
- Oct 13, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 13, 2025, the board of directors (the “Board”) of Ardelyx, Inc. (the “Company”) appointed Sue Hohenleitner as chief financial officer (“CFO”) and principal financial officer, effective November 4, 2025.”
- Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
- Dec 17, 2025Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On December 17, 2025, Elizabeth Grammer informed Ardelyx, Inc. (the “Company”) of her resignation as the Company’s Chief Legal and Administrative Officer, effective December 31, 2025 (the “Resignation Date”).”
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Ardelyx
For Ardelyx, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ARDX page.
Other recent filings by Laura A Williams, Chief Patient Officer
- SEC Form 4 at Ardelyx (ARDX)Aug 28, 2025
- SEC Form 4 at Ardelyx (ARDX)Aug 26, 2025
- SEC Form 4 at Ardelyx (ARDX)May 23, 2025
- SEC Form 4 at Ardelyx (ARDX)Feb 21, 2025
- SEC Form 4 at Ardelyx (ARDX)Nov 22, 2024
The full history of Laura A Williams, Chief Patient Officer is on the profile page.
How this filing works
Other disclosures at Ardelyx
- SEC Form 13F-HRAug 14, 2026
- USAspending.gov award recordJun 29, 2026
- USAspending.gov award recordJun 29, 2026
- USAspending.gov award recordJun 12, 2026
- USAspending.gov award recordMay 28, 2026
- USAspending.gov award recordApr 10, 2026
Everything OQRO holds on this company is on its ARDX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
